- Home
- RVPH vs EDSA Comparison
RVPH vs EDSA Comparison
Compare RVPH & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- EDSA
- Stock Information
- Founded
- RVPH 2006
- EDSA 2015
- Country
- RVPH United States
- EDSA Canada
- Employees
- RVPH N/A
- EDSA N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- RVPH Health Care
- EDSA Health Care
- Exchange
- RVPH Nasdaq
- EDSA Nasdaq
- Market Cap
- RVPH 18.1M
- EDSA 18.6M
- IPO Year
- RVPH N/A
- EDSA N/A
- Fundamental
- Price
- RVPH $0.57
- EDSA $2.64
- Analyst Decision
- RVPH Strong Buy
- EDSA Strong Buy
- Analyst Count
- RVPH 6
- EDSA 2
- Target Price
- RVPH $4.50
- EDSA $13.00
- AVG Volume (30 Days)
- RVPH 19.3M
- EDSA 135.8K
- Earning Date
- RVPH 11-13-2025
- EDSA 12-12-2025
- Dividend Yield
- RVPH N/A
- EDSA N/A
- EPS Growth
- RVPH N/A
- EDSA N/A
- EPS
- RVPH N/A
- EDSA N/A
- Revenue
- RVPH N/A
- EDSA N/A
- Revenue This Year
- RVPH N/A
- EDSA N/A
- Revenue Next Year
- RVPH N/A
- EDSA N/A
- P/E Ratio
- RVPH N/A
- EDSA N/A
- Revenue Growth
- RVPH N/A
- EDSA N/A
- 52 Week Low
- RVPH $0.25
- EDSA $1.55
- 52 Week High
- RVPH $4.28
- EDSA $4.49
- Technical
- Relative Strength Index (RSI)
- RVPH 52.50
- EDSA 54.28
- Support Level
- RVPH $0.42
- EDSA $2.42
- Resistance Level
- RVPH $0.69
- EDSA $2.95
- Average True Range (ATR)
- RVPH 0.11
- EDSA 0.21
- MACD
- RVPH -0.02
- EDSA 0.00
- Stochastic Oscillator
- RVPH 32.74
- EDSA 47.33
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.